TherapyTherapyТерапия2412-40362713-1823Bionika Media28875410.18565/therapy.2022.1.50-59ArticlesСтатьиResearch ArticleBiomarkers in cardiology: lipocalin associated with neutrophil gelatinase (NGAL) and cardiovascular diseasesБиомаркеры в кардиологии: липокалин, связанный с желатиназой нейтрофилов (NGAL), и сердечно-сосудистые заболеванияAlievaAmina M.АлиеваАмина Магомедовна

PhD, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine

к.м.н., доцент кафедры госпитальной терапии № 2 лечебного факультета

amisha_alieva@mail.ruTeplovaNatalia V.ТепловаНаталья Вадимовна

MD, professor, head of the Department of clinical pharmacology of the Faculty of general medicine

д.м.н., профессор, заведующий кафедрой клинической фармакологии лечебного факультета

ReznikElena V.РезникЕлена Владимировна

MD, professor, head of the Department of propaedeutics of internal diseases of the Faculty of general medicine

д.м.н., профессор, зав. кафедрой пропедевтики внутренних болезней лечебного факультета

elenaresnik@gmail.comValievRamiz K.ВалиевРамиз Камраддинович

PhD, head of the Department of oncosurgery No. 2

к.м.н., зав. онкохирургическим отделением № 2

radiosurgery@bk.ruRakhaevAlik M.РахаевАлик Магомедович

MD, professor, head of the expert team

д.м.н., профессор, руководитель экспертного состава

alikrahaev@yandex.ruKudaevaMadina V.КудаеваМадина Владимировна

doctor for medical and social expertise, therapist of expert team

врач по медико-социальной экспертизе, терапевт экспертного состава

lyalyusha1974@mail.ruAkhmatovIslam Z.АхматовИслам Заурбекович

student at the Faculty of general medicine

студент лечебного факультета

ArakelyanRosa A.АракелянРоза Арамовна

student at the Faculty of general medicine

студентка лечебного факультета

elmira.sharm@yandex.ruNikitinIgor G.НикитинИгорь Геннадиевич

MD, professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine

м.н., профессор, зав. кафедры госпитальной терапии № 2 лечебного факультета

igor.nikitin.64@mail.ruN.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of RussiaФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииA.S. Loginov Moscow Clinical Research Center of the Healthcare Department of MoscowГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. МосквыMain Bureau of Medical and Social Expertise in the Kabardino-Balkarian Republic of the Ministry of Labor and Social Protection of RussiaФКУ «Главное бюро медико-социальной экспертизы по Кабардино-Балкарской Республике» Министерства труда и социальной защиты РоссииV.I. Razumovsky Saratov State Medical University of the Ministry of Healthcare of RussiaФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России1501202281VOL 8, NO1 (2022)ТОМ 8, №1 (2022)505926022023Copyright ©; 2022, “Bionika Media” LLCCopyright ©; 2022, ООО «Бионика Медиа»2022“Bionika Media” LLCООО «Бионика Медиа»https://journals.eco-vector.com/2412-4036/about/editorialPolicieshttps://journals.eco-vector.com/2412-4036/article/view/288754

The purpose of this review is to consider neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic and prognostic marker in cardiovascular diseases. The results of various studies show that there is a huge scientific interest in the study of NGAL in cardiovascular pathology. It has been suggested that NGAL may be a marker of atherosclerosis, which was confirmed by a number of studies that demonstrated the overexpression of NGAL in atherosclerotic plaques in areas with high proteolytic activity. It has also been suggested that the role of NGAL in patients with coronary artery disease is associated with matrix metalloproteinase-9. Several studies have reported that NGAL is a marker of adverse cardiovascular events in patients with heart failure.

Цель обзора - рассмотреть липокалин, связанный с желатиназой нейтрофилов (NGAL), в качестве диагностического и прогностического маркера при сердечно-сосудистой патологии. Результаты различных исследований свидетельствуют об огромном научном интересе к изучению NGAL при кардиоваскулярных заболеваниях. По одной из гипотез, он может служить маркером атеросклероза: это подтверждено рядом исследований, продемонстрировавших чрезмерную экспрессию NGAL в атеросклеротических бляшках в зонах с высокой протеолитической активностью. Также высказано предположение, что роль NGAL у пациентов с ишемической болезнью сердца связана с матриксной металлопротеиназой-9. В ряде исследований сообщается, что NGAL является маркером неблагоприятных сердечно-сосудистых событий у пациентов с сердечной недостаточностью.

biological markerslipocalin associated with neutrophil gelatinase (NGAL)cardiovascular diseasesmyocardial infarctionheart failureбиологические маркерылипокалинсвязанный с желатиназой нейтрофилов (NGAL)сердечно-сосудистые заболеванияинфаркт миокардасердечная недостаточностьRoth G.A., Mensah G.A., Johnson C.O. et al. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25): 2982-3021. https://dx.doi.org/10.10167j.jacc.2020.11.010.Алиева А.М., Резник Е.В., Гасанова Э.Т. с соавт. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018; 5: 333-345.Алиева А.М., Пинчук Т.В., Алмазова И.И. с соавт. Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью. Consilium Medicum. 2021; 6: 522-526Xu S.Y., Carlson M., Engström A. et al. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest. 1994; 54(5): 365-76. https://dx.doi.org/10.3109/00365519409088436.Kjeldsen L., Johnsen A.H., Sengelov H. et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993; 268(14): 10425-32.Yan Q.W., Yang Q., Mody N. et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes. 2007; 56(10): 2533-40. https://dx.doi.org/10.2337/db07-0007.Yang J., Blum A., Novak T. et al. An epithelial precursor is regulated by the ureteric bud and by the renal stroma. Dev Biol. 2002; 246(2): 296-310. https://dx.doi.org/10.1006/dbio.2002.0646.Meldrum K.K., Hile K., Meldrum D.R. et al. Simulated ischemia induces renal tubular cell apoptosis through a nuclear factor-kappaB dependent mechanism. J Urol. 2002; 168(1): 248-52. https://dx.doi.org/10.1006/jsre.2001.6201.Bauvois B., Susin S.A. Revisiting neutrophil gelatinase-associated lipocalin (NGAL) in cancer: Saint or sinner? Cancers (Basel). 2018; 10(9): 336. https://dx.doi.org/10.3390/cancers10090336.Che K., Han W., Zhang M. et al. Role of neutrophil gelatinase-associated lipocalin in renal cell carcinoma. Oncol Lett. 2021; 21(2): 148. https://dx.doi.org/10.3892/ol.2020.12409.Tsakogiannis D., Kalogera E., Zagouri F. et al. Determination of FABP4, RBP4 and the MMP-9/NGAL complex in the serum of women with breast cancer. Oncol Lett. 2021; 21(2): 85. https://dx.doi.org/10.3892/ol.2020.12346.Hemdahl A.L., Gabrielsen A., Zhu C. et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol. 2006; 26(1):136-42. https://dx.doi.org/10.1161/01.ATV.0000193567.88685.f4.Sivalingam Z., Larsen S.B., Grove E.L. et al. Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease. Clin Chem Lab Med. 2017; 56(1): 5-18. https://dx.doi.org/10.1515/cclm-2017-0120.Eilenberg W., Stojkovic S., Kaider A. et al. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clin Chem Lab Med. 2017; 56(1): 147-56. https://dx.doi.org/10.1515/cclm-2017-0156.Yan L., Borregaard N., Kjeldsen L. et al. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001; 276: 37258-65. https://dx.doi.org/10.1074/jbc.M106089200.Eilenberg W., Stojkovic S., Kaider A., et al. Neutrophil gelatinase associated lipocalin (NGAL) for identification of unstable plaques in patients with asymptomatic carotid stenosis. Eur J Vasc Endovasc Surg. 2019; 57(6): 768-77. https://dx.doi.org/10.1016/j.ejvs.2018.12.029.Paulsson J., Dadfar E., Held C. et al. Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis. 2007; 192(2): 328-34. https://dx.doi.org/10.1016/j.atherosclerosis.2006.08.003.Katagiri M., Takahashi M., Doi K. et al. Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease. Heart Vessels. 2016; 31(10): 1595-602. https://dx.doi.org/10.1007/s00380-015-0776-8.Woitas R.P., Scharnagl H., Kleber M.E. et al. Neutrophil gelatinase-associated lipocalin levels are U-shaped in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study-Impact for mortality. PLoS One. 2017; 12(2): e0171574. https://dx.doi.org/10.1371/journal.pone.0171574.Li C., Zhang Z., Peng Y. et al. Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease. PLoS One. 2019; 14(8): e0220841. https://dx.doi.org/10.1371/journal.pone.0220841.Chong J.J.H., Prince R.L., Thompson P.L. et al. Association between plasma neutrophil gelatinase-associated lipocalin and cardiac disease hospitalizations and deaths in older women. J Am Heart Assoc. 2019; 8(1): e011028. https://dx.doi.org/10.1161/JAHA.118.011028.Soylu K., Nar G., Aksan G. et al. Serum neutrophil gelatinase-associated lipocalin levels and aortic stiffness in noncritical coronary artery disease. Cardiorenal Med. 2014; 4(3-4): 147-54. https://dx.doi.org/10.1159/000365200.Wong Y.K., Cheung C.Y.Y., Tang C.S. et al. Age-biomarkers-clinical risk factors for prediction of cardiovascular events in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2018; 38(10): 2519-27. https://dx.doi.org/10.1161/ATVBAHA.118.311726.Liu H., Wan X., Shi Y. et al. Neutrophil gelatinase-associated lipocalin contributes to increased risk of cardiovascular death after acute coronary syndrome.Int J Gen Med. 2021; 14: 4887-95. https://dx.doi.org/10.2147/IJGM.S328022.Зыков М.В., Кашталап В.В., Быкова И.С. с соавт. Клиническое и прогностическое значение сывороточного интерлейкина-18 у больных инфарктом миокарда с подъемом сегмента ST. Российский кардиологический журнал. 2015; 11: 70-74Avci A., Ozturk B., Demir K. et al. The prognostic utility of plasma NGAL levels in ST segment elevation in myocardial infarction patients. Adv Prev Med. 2020; 2020: 4637043. https://dx.doi.org/10.1155/2020/4637043.Шаленкова М.А., Михайлова З.Д., Климкин П.Ф. NGAL как маркер некоторых внепочечных осложнений при остром коронарном синдроме. Кардиология. 2018; S3: 19-26.Sabanovic-Bajramovic N., Hodzic E., Iglica A. et al. Neutrophil gelatinase-associated lipocalin is a predictor of complications in the early phase of ST-elevation myocardial infarction. Med Glas (Zenica). 2020; 17(2): 328-34. https://dx.doi.org/10.17392/1139-20.Nymo S.H., Hartford M., Ueland T. et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) concentration is independently associated with mortality in patients with acute coronary syndrome.Int J Cardiol. 2018; 262: 79-84. https://dx.doi.org/10.1016/j.ijcard.2018.03.028.Lahiri A., Alex A.G., George P.V. Estimating the prevalence of elevated plasma neutrophil gelatinase associated lipocalin level in patients with acute coronary syndromes and its association with outcomes. Indian Heart J. 2018; 70(2): 220-24. https://dx.doi.org/10.1016/j.ihj.2017.06.005.Frydland M., Mogelvang R., Moller J.E. et al. Neutrophil gelatinase-associated lipocalin (NGAL) measured at admission is associated with development of late cardiogenic shock and mortality in patients with ST-segment elevation myocardial infarction. Shock. 2021; 56(2): 255-59. https://dx.doi.org/10.1097/SHK.0000000000001721.Yndestad A., Landna L., Ueland T. et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009; 30(10): 1229-36. https://dx.doi.org/10.1093/eurheartj/ehp088.Villacorta H., Santos R.A., Marroig M.A. et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin in patients with heart failure. Rev Port Cardiol. 2015; 34(7-8): 473-78. https://dx.doi.org/10.1016/j.repc.2015.02.003.Damman K., Masson S., Hillege H.L. et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011; 32(21): 2705-12. https://dx.doi.org/10.1093/eurheartj/ehr190.Maisel A.S., Mueller C., Fitzgerald R. et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011; 13(8): 846-51. https://dx.doi.org/10.1093/eurjhf/hfr087.Oikonomou E., Tsalamandris S., Karlis D. et al. The association among biomarkers of renal and heart function in patients with heart failure: the role of NGAL. Biomark Med. 2018; 12(12): 1323-30. https://dx.doi.org/10.2217/bmm-2018-0100.Labr K., Spinar J., Parenica J. et al. Renal functions and prognosis stratification in chronic heart failure patients and the importance of neutrophil gelatinase-associated lipocalin. Kidney Blood Press Res. 2018; 43(6): 1865-77. https://dx.doi.org/10.1159/000495819.Алиева А.М., Алмазова И.И., Пинчук Т.В. с соавт. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020; 5: 83-86.Алиева А.М., Байкова И.Е., Кисляков В.А. с соавт. Галектин-3: диагностическая и прогностическая ценность определения у пациентов с хронической сердечной недостаточностью. Терапевтический архив. 2019; 9: 145-149